Six Groups Slam Drug Makers’ 340B Pricing Conditions on Hepatitis C Medicines

Six HIV/AIDS and viral hepatitis advocacy groups issued a joint statement criticizing AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.

Six groups that support patients with HIV/AIDS and viral hepatitis and their caregivers issued a joint statement yesterday criticizing drug manufacturers AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.

Please

Read More »

BMS Fleshes Out How It Will Use Claims Data for 340B Myeloma Drug Purchases

BMS has released its terms of use for the claims data providers must give it in exchange for access to 340B pricing on Revlimid, Pomalyst, and Thalomid.

Bristol Myers Squibb has disclosed its terms of use for the drug claims data that providers must give it in exchange for access to 340B pricing on BMS’s oral oncology drugs Revlimid, Pomalyst, and Thalomid.

Read More »

Astellas Providing Refunds for 340B Overcharges from Q3 2020 Through Q2 2021

Astellas is issuing 340B covered entities refunds for overcharges on Xtandi and Myrbetriq for the period from Q3 2020 through Q2 2021.

Astellas Pharma is issuing 340B covered entities refunds for overcharges on three NDCs for its prostate cancer treatment Xtandi and on four NDCs for its overactive bladder medication Myrbetriq for the period from Q3 2020 through Q2 2021.

Read More »

Lilly Providing Refunds for 340B Overcharges During Q3 2019

Drug company Lilly is providing refunds for 340B overcharges on 14 NDCs during 3Q 2019.

Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the

Read More »

340B Sales Growth Rate Slowed in 2021, the First Year of 340B Contract Pharmacy Restrictions

340B drug sales grew at a slower rate in 2021, the first year of 340B contract pharmacy restrictions, IQVIA reports.

Prescription drug sales at 340B-discounted prices grew 15.9% year-on-year from 2020 to 2021, drug industry consulting and contract research firm IQVIA reports, an annual growth rate below that for the two preceding years.

Please Login or

Read More »

340B Report Publisher and CEO Slafsky: 340B Contract Pharmacy Program Has Fractured Into 17 Pieces

Drug manufacturers' 340B contract pharmacy actions have seemingly fractured the 340B program into pieces, 340B Publisher and CEO Ted Slafsky says.

“The 340B contract pharmacy program has seemingly fractured into 17 programs, one governed by the federal government and 16 others with their own standards determined by pharmaceutical manufacturers,” 340B Publisher and CEO Ted Slafsky observes in his latest column for

Read More »

340B ESP Makes Changes to Its Terms of Use that Entities Must Accept

A screen capture from 340B ESP's home page. The drug industry contractor that helps manufacturers implement 340B contract pharmacy restrictions yesterday updated its terms of use for 340B covered entities that decide to use its portal.

Second Sight Solutions, the drug industry contractor that collects 340B contract pharmacy claims data on manufacturers’ behalf through its 340B ESP portal, has revised the terms of use that covered entities must accept when they register to use the portal.

Read More »

Exclusive: Gilead Responds to Health Center Group’s Criticism of its 340B Contract Pharmacy Policy

Gilead told NACHC in a letter yesterday it is concerned about the group's criticism of the company's new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments.

Drug manufacturer Gilead told the National Association of Community Health Centers yesterday that NACHC’s condemnation last month of Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments “seem to represent a misunderstanding of this integrity

Read More »

340B Advocacy Group Expresses Concern About Apparent Unique Feature in J&J’s Contract Pharmacy Policy

RWC-340B says Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently applies also to hospitals’ non-340B-purchased “own use” drugs.

Drug manufacturer Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently apply also to hospitals’ non-340B-purchased “own use” drugs, the group Ryan White Clinics for 340B Access has told its members.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content